Vanguard Asset Management
HAE icon

Vanguard Asset Management’s Haemonetics HAE Stock Holding History

Vanguard Asset Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.35M Buy
44,685
+2,395
+6% +$154K ﹤0.01% 1286
2026
Q1 		$2.38M Buy
+42,290
New +$2.75M ﹤0.01% 1377

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Asset Management's HAE Position: Q2 2026 in Review

Vanguard Asset Management increased its Haemonetics (HAE) stake by 5.7% in Q2 2026, buying an estimated $154K and bringing the position to 44,685 shares worth $3.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1286.

Vanguard Asset Management first reported a position in HAE in Q1 2026 and has held it in 2 quarters since. 325 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Vanguard Asset Management held 44,685 shares of Haemonetics worth $3.35M as of Q2 2026.
  • Vanguard Asset Management bought 2,395 Haemonetics shares in Q2 2026, an estimated $154K.
  • Haemonetics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1286 holding.
  • Vanguard Asset Management first reported a position in Haemonetics in Q1 2026 and has held it in 2 quarters since.
  • 325 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.